CASZ1 upregulates PI3K-AKT-mTOR signaling and promotes T-cell acute lymphoblastic leukemia
Bruno A. Cardoso,
Mafalda Duque,
Ana Gírio,
Rita Fragoso,
Mariana L. Oliveira,
James R. Allen,
Leila R. Martins,
Nádia C. Correia,
André Bortolini Silveira,
Alexandra Veloso,
Shunsuke Kimura,
Lisa Demoen,
Filip Matthijssens,
Sima Jeha,
Cheng Cheng,
Ching-Hon Pui,
Ana R. Grosso,
João L. Neto,
Sérgio F. de Almeida,
Pieter Van Vlieberghe,
Charles G. Mullighan,
J. Andres Yunes,
David M. Langenau,
Françoise Pflumio,
João T. Barata
Affiliations
Bruno A. Cardoso
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon
Mafalda Duque
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon
Ana Gírio
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon
Rita Fragoso
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon
Mariana L. Oliveira
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon
James R. Allen
MGH Pathology and Harvard Medical School, Charlestown MA 02129
Leila R. Martins
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon
Nádia C. Correia
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon
André Bortolini Silveira
Laboratório de Biologia Molecular, Centro Infantil Boldrini, Campinas, SP
Alexandra Veloso
MGH Pathology and Harvard Medical School, Charlestown MA 02129
Shunsuke Kimura
Department of Pathology, Center of Excellence for Leukemia Studies, and Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis TN
Lisa Demoen
Department of Biomolecular Medicine, Ghent University, and Cancer Research Institute Ghent (CRIG), Ghent, Belgium
Filip Matthijssens
Department of Biomolecular Medicine, Ghent University, and Cancer Research Institute Ghent (CRIG), Ghent, Belgium
Sima Jeha
Department of Oncology, St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center, Memphis TN, US; Department of Global Pediatric Medicine, St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center, Memphis TN
Cheng Cheng
Department of Biostatistics, St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center, Memphis TN
Ching-Hon Pui
Department of Oncology, St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center, Memphis TN, US; Department of Global Pediatric Medicine, St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center, Memphis TN, US; Department of Pathology, St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center, Memphis TN
Ana R. Grosso
Associate Laboratory i4HB - Institute for Health and Bioeconomy, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal; UCIBIO – Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516 Caparica
João L. Neto
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon
Sérgio F. de Almeida
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon
Pieter Van Vlieberghe
Department of Biomolecular Medicine, Ghent University, and Cancer Research Institute Ghent (CRIG), Ghent, Belgium
Charles G. Mullighan
Department of Pathology, Center of Excellence for Leukemia Studies, and Hematological Malignancies Program, St. Jude Children's Research Hospital, Memphis TN
J. Andres Yunes
Laboratório de Biologia Molecular, Centro Infantil Boldrini, Campinas, SP
David M. Langenau
MGH Pathology and Harvard Medical School, Charlestown MA 02129
Françoise Pflumio
Université Paris-Saclay, INSERM, iRCM/IBFJ CEA, UMR Stabilité Génétique Cellules Souches et Radiations, F-92265, Fontenay-aux-Roses, France; OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Saint-Louis Hospital, 75010 Paris
João T. Barata
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon
CASZ1 is a conserved transcription factor involved in neural development, blood vessel assembly and heart morphogenesis. CASZ1 has been implicated in cancer, either suppressing or promoting tumor development depending on the tissue. However, the impact of CASZ1 on hematological tumors remains unknown. Here, we show that the T-cell oncogenic transcription factor TAL1 is a direct positive regulator of CASZ1, that T-cell acute lymphoblastic leukemia (T-ALL) samples at diagnosis overexpress CASZ1b isoform, and that CASZ1b expression in patient samples correlates with PI3K-AKT-mTOR signaling pathway activation. In agreement, overexpression of CASZ1b in both Ba/F3 and T-ALL cells leads to the activation of PI3K signaling pathway, which is required for CASZ1b-mediated transformation of Ba/F3 cells in vitro and malignant expansion in vivo. We further demonstrate that CASZ1b cooperates with activated NOTCH1 to promote T-ALL development in zebrafish, and that CASZ1b protects human T-ALL cells from serum deprivation and treatment with chemotherapeutic drugs. Taken together, our studies indicate that CASZ1b is a TAL1-regulated gene that promotes T-ALL development and resistance to chemotherapy.